rifapentine (Priftin)

12/01/2005 - "To test this hypothesis we evaluated the sterilizing activity of improved once-weekly rifapentine-based continuation phase regimens in a murine model that mimics the treatment of high-risk patients with tuberculosis. "
05/08/2023 - "Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial."
06/10/2016 - "The present study aims to address this knowledge gap, using PLGAs with monomer ratios of 50:50, 75:25 and 85:15, MW ranged 24 - 240kDa and an anti-tuberculosis (TB) drug, rifapentine. "
08/01/2014 - "In this exploratory study, we characterized the free plasma fraction of rifapentine in 41 patients with tuberculosis. "
03/01/2010 - "Study 29 is currently underway, in which rifapentine was introduced in the experimental regimen for active tuberculosis treatment."

01/01/2022 - "Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised controlled trial."
01/01/2011 - "Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability. "
06/01/2002 - "Rifapentine 900-mg, once-weekly dosing appears to be safe and well tolerated and is being evaluated in Phase III efficacy trials of treatment of latent tuberculosis. "
12/01/2020 - "Estimated Population-Level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States."
01/01/2020 - ": To characterize rifapentine population pharmacokinetics, including autoinduction, and determine optimal dosing strategies for short-course rifapentine-based regimens for latent tuberculosis infection.Methods"

03/01/2015 - "Inhaled delivery of rifapentine has the potential to selectively enhance therapeutic efficacy at the pulmonary site of infection whilst minimising systemic exposure and related toxicity. "
03/01/2014 - "Recent animal studies have shown that more frequent administration of rifapentine could shorten treatment times, for both latent and active TB infection. "
01/01/2017 - "In 2014, rifapentine was approved for the treatment of latent TB infection in patients at high risk of progression to active disease and is currently under evaluation by the European Medicines Agency. "
06/01/2014 - "Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices."
10/01/1999 - "A well-tolerated oral rifapentine dose produced rapid and sustained plasma drug concentrations in adolescents that should effectively treat infections caused by M. "

05/18/2023 - "We conducted a cluster-randomized, controlled trial to investigate whether single-dose rifapentine is effective in preventing leprosy in household contacts of patients with leprosy. "
08/17/2023 - "Rifapentine in Household Contacts of Patients with Leprosy."
08/17/2023 - "Rifapentine in Household Contacts of Patients with Leprosy. "
05/18/2023 - "The incidence of leprosy among household contacts over 4 years was lower with single-dose rifapentine than with no intervention. "
05/18/2023 - "Single-Dose Rifapentine in Household Contacts of Patients with Leprosy."

08/17/2002 - "Rifapentine once a week is safe and effective for treatment of pulmonary tuberculosis in HIV-negative people without cavitation on chest radiography. "
01/01/2023 - "Rationale: We developed a standardized method, possible poor treatment response (PPTR), to help ascertain efficacy endpoints in Study S31/A5349 (NCT02410772), an open-label trial comparing two 4-month rifapentine-based regimens with a standard 6-month regimen for the treatment of pulmonary tuberculosis (TB). "
08/01/2017 - "Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials."
07/01/2015 - "Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis."
05/15/2015 - "Erratum: daily rifapentine for treatment of pulmonary tuberculosis: a randomized, dose-ranging trial."